The Biomarker Cascade: How Your Heart Sends Distress Signals in a Specific Order — And Why Most People Only Get Tested When It's Almost Too Late

The biomarker concept here starts with the endothelium—the single-cell layer lining blood vessels—because endothelial activation/dysfunction is an early feature in many cardiovascular disease pathways. Mechanistically, endothelial dysfunction is commonly described as reduced nitric-oxide–mediated vasodilation together with higher oxidative stress and a more adhesive/pro-inflammatory endothelial surface that can increase expression and shedding of adhesion molecules such as ICAM-1 and VCAM-1 [15].

One proposed early readout is endothelial progenitor cells (EPCs), a heterogeneous population involved in vascular repair. Reviews suggest EPC number/function often correlate inversely with cardiovascular risk and may change before overt clinical disease, but methods for defining and measuring EPCs vary widely, which limits their standardization as a routine biomarker [3].

It’s also important to avoid over-interpreting a single marker: nitric-oxide “availability” is rarely measured directly in clinical labs, and soluble adhesion molecules can rise in multiple inflammatory states. In practice, these endothelial-related measures are best understood as indirect signals of endothelial activation rather than stand-alone diagnostic tests [15].

As vascular dysfunction persists, inflammatory signaling often becomes more measurable systemically. CRP is a downstream acute-phase reactant largely induced by cytokines such as IL-6, and both have been repeatedly linked to cardiovascular risk in epidemiology and biomarker reviews [9][15]. However, elevations are not specific to vascular disease; infection, chronic inflammatory disorders, adiposity, and other conditions can also raise these markers.

Mechanistically, innate immune cells contribute to this process. Neutrophils are not just bystanders: they release inflammatory mediators and can form neutrophil extracellular traps (NETs), which have been implicated in thrombosis and vascular inflammation in mechanistic and translational literature [2]. This helps explain why inflammatory biomarkers can track with both atherosclerotic activity and thrombotic risk, even when imaging still appears “normal.”

Because many phytonutrients are studied for effects on inflammatory biomarkers, it’s reasonable to note that clinical trials/meta-analyses have evaluated compounds such as hesperidin and broader phytonutrient categories for changes in cardiometabolic biomarkers (including inflammatory markers), with mixed results across populations and outcomes [7][8]. These findings support biomarker plausibility, but they do not establish that changing CRP/IL-6 via supplementation necessarily translates into fewer cardiovascular events in all groups.

With longer-standing hemodynamic load and myocardial wall stress, the heart can increase production of natriuretic peptides—BNP and NT-proBNP—which are central clinical biomarkers of cardiac stress and heart-failure physiology [10]. These peptides are part of a compensatory system that promotes natriuresis and vasodilation and counter-regulates neurohormonal pathways [10].

Interpreting natriuretic peptides requires context. They can rise with many forms of cardiac strain (e.g., pressure/volume overload, atrial arrhythmias) and can also vary with age, kidney function, and body composition, so they are not a pure “remodeling marker” [10]. In a cascade framing, they are best positioned as signals that cardiac wall stress has become biologically meaningful—often later than endothelial activation/inflammation for many pathways, but not in a fixed order for every person or condition [9][15].

Troponins are structural proteins released into blood with myocardial injury. High-sensitivity assays can detect small increases, and biomarker reviews emphasize that troponin elevation reflects injury rather than a single diagnosis—multiple acute and chronic conditions can cause measurable troponin without an acute coronary event [15].

In the cascade framing, troponin sits at the “injury” end of the spectrum: it is closer to cell damage than endothelial activation or systemic inflammation. Even so, the boundary is not absolute. Some people show low-level chronic troponin elevations that track with underlying cardiac stress or comorbidity, and acute injury can re-intensify inflammatory signaling, creating overlapping waves rather than a clean, one-direction sequence [9][15]. The practical takeaway for interpretation is to treat troponin as a marker of myocardial injury burden and timing—not as a stand-alone explanation of cause.

A useful way to organize cardiovascular biomarkers is by what tissue/process they primarily “report” on: endothelial activation/dysfunction, systemic inflammation, cardiac wall stress, and myocardial injury. This cascade is a heuristic—not a strict timeline—but it can clarify why different tests answer different biological questions and why relying only on late injury markers misses earlier, more upstream signals of vascular stress.